Your Health, We Care
The most common (>20%) adverse reactions are diarrhea, rash, stomatitis, vomiting, decreased appetite, paronychia, nausea, musculoskeletal pain, dry skin, fatigue, cough, pruritus, and decreased weight. The most common (≥2%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes, increased amylase, increased lipase, decreased potassium, decreased red blood cells, increased creatinine, decreased magnesium and increased alanine aminotransferase.
from FDA，2023.09
Mobocertinib is a targeted therapy drug for non-small cell lung cancer (NSCLC) w···【more】
Release date：2026-02-26Recommended：33
Exkivityimproves patient outcomes by inhibiting specific mutant kinases and bloc···【more】
Release date：2024-08-08Recommended：247
Exkivity effectively inhibits the growth and spread of tumor cells by precisely ···【more】
Release date：2024-08-08Recommended：279
Exkivityis an innovative third-representative dermal growth factor receptor (EGF···【more】
Release date：2024-08-08Recommended：230
